Please check your internet connection and try again.
# Sompraz HP (Pantoprazole HP)
## Overview
Sompraz HP is a combination product containing pantoprazole, a proton pump inhibitor (PPI), and specific antibiotics (amoxicillin and clarithromycin) used for the eradication of *Helicobacter pylori*. Pantoprazole suppresses gastric acid production, while amoxicillin and clarithromycin target the bacteria.
## Primary Indications
* Treatment of *Helicobacter pylori* infection in patients with duodenal or gastric ulcers.
## Adult Dosing
The typical adult regimen is:
* Pantoprazole 40 mg orally once daily
* Amoxicillin 1000 mg orally twice daily
* Clarithromycin 500 mg orally twice daily
This regimen is generally prescribed for 7 to 14 days. Local resistance patterns may influence the choice of antibiotics or the duration of therapy.
## Pediatric Dosing
Specific pediatric dosing for Sompraz HP is not established. Dosing for *H. pylori* eradication in children should be guided by age-appropriate antibiotic regimens and PPI dosing, often requiring individualization based on weight and local guidelines.
## Dose Adjustments
* **Renal Impairment:** No dose adjustment is typically required for pantoprazole in mild to moderate renal impairment. In severe impairment, caution is advised. Antibiotic doses may need adjustment based on renal function.
* **Hepatic Impairment:** For pantoprazole, a maximum dose of 20 mg once daily is recommended in severe hepatic impairment. Antibiotic doses may need adjustment.
## Contraindications
* Known hypersensitivity to pantoprazole, amoxicillin, clarithromycin, other macrolides, or penicillins.
* History of severe immediate hypersensitivity reactions to other beta-lactam antibiotics.
* Concomitant use with rifampin, ritonavir, or cisapride.
* Severe hepatic or renal impairment (relative contraindication for certain components or doses).
* Certain electrolyte abnormalities.
## Adverse Effects
Common adverse effects include:
* **Gastrointestinal:** Diarrhea, nausea, abdominal pain, vomiting, constipation, bloating.
* **Taste disturbances:** Dysgeusia (altered taste).
* **Headache.**
* **Allergic reactions:** Rash, pruritus.
* **Clarithromycin-specific:** QT prolongation (rare), potential for *Clostridium difficile*-associated diarrhea.
* **Amoxicillin-specific:** Hypersensitivity reactions, rash.
## Key Drug Interactions
* **Warfarin:** Increased INR and bruising. Monitor INR closely.
* **Methotrexate:** PPIs may increase serum methotrexate levels, potentially leading to toxicity.
* **CYP2C19 substrates:** Pantoprazole can inhibit CYP2C19, affecting metabolism of drugs like clopidogrel.
* **Clarithromycin:** Inhibits CYP3A4. Interactions with drugs metabolized by CYP3A4 (e.g., statins, certain calcium channel blockers, benzodiazepines).
* **Drugs prolonging QT interval:** Increased risk when used with clarithromycin.
## Monitoring
* **Therapeutic response:** Monitor for resolution of ulcer symptoms and signs of *H. pylori* eradication (e.g., repeat urea breath test or stool antigen test after completion of therapy).
* **Adverse effects:** Monitor for gastrointestinal disturbances, allergic reactions, and signs of *C. difficile* infection.
* **Electrolytes:** Especially if hypomagnesemia has occurred with long-term PPI use.
## Clinical Pearls
* Administer pantoprazole before breakfast, on an empty stomach, for optimal acid suppression.
* The antibiotic components should be taken with food to improve tolerability.
* Ensure patients complete the full course of antibiotics, even if they feel better, to maximize eradication rates and minimize resistance.
* Consider local resistance patterns for *H. pylori* when choosing therapy.
* Be aware of the potential for antibiotic resistance, particularly to clarithromycin.
***
*This information is intended for healthcare professionals and does not substitute for a thorough review of the complete prescribing information and relevant literature. Always verify current drug information with official product labeling and consult with clinical experts.*
